Chilton Capital Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.07K | Buy |
100
+64
| +178% | +$3.73K | ﹤0.01% | 526 |
|
|
2025
Q4 | $1.94K | Sell |
36
-21,275
| -100% | -$1.02M | ﹤0.01% | 542 |
|
|
2025
Q3 | $961K | Sell |
21,311
-154
| -0.7% | -$7.19K | 0.03% | 139 |
|
|
2025
Q2 | $994K | Sell |
21,465
-1,346
| -6% | -$66.1K | 0.04% | 134 |
|
|
2025
Q1 | $1.39M | Sell |
22,811
-1,671
| -7% | -$97.4K | 0.06% | 110 |
|
|
2024
Q4 | $1.38M | Sell |
24,482
-3,400
| -12% | -$190K | 0.06% | 114 |
|
|
2024
Q3 | $1.44M | Hold |
27,882
| – | – | 0.06% | 113 |
|
|
2024
Q2 | $1.16M | Buy |
27,882
+51
| +0.2% | +$2.28K | 0.05% | 121 |
|
|
2024
Q1 | $1.51M | Sell |
27,831
-999
| -3% | -$50.9K | 0.07% | 112 |
|
|
2023
Q4 | $1.48M | Buy |
28,830
+3,670
| +15% | +$193K | 0.08% | 112 |
|
|
2023
Q3 | $1.46M | Sell |
25,160
-300
| -1% | -$18.4K | 0.08% | 108 |
|
|
2023
Q2 | $1.63M | Hold |
25,460
| – | – | 0.09% | 102 |
|
|
2023
Q1 | $1.76M | Sell |
25,460
-1,570
| -6% | -$111K | 0.1% | 97 |
|
|
2022
Q4 | $1.94M | Hold |
27,030
| – | – | 0.12% | 98 |
|
|
2022
Q3 | $1.92M | Hold |
27,030
| – | – | 0.13% | 94 |
|
|
2022
Q2 | $2.08M | Buy |
27,030
+674
| +3% | +$51.3K | 0.13% | 96 |
|
|
2022
Q1 | $1.93M | Buy |
26,356
+229
| +0.9% | +$15.4K | 0.1% | 104 |
|
|
2021
Q4 | $1.63M | Buy |
26,127
+206
| +0.8% | +$12.1K | 0.08% | 115 |
|
|
2021
Q3 | $1.53M | Sell |
25,921
-9,500
| -27% | -$626K | 0.09% | 114 |
|
|
2021
Q2 | $2.37M | Buy |
35,421
+22,031
| +165% | +$1.44M | 0.14% | 98 |
|
|
2021
Q1 | $845K | Sell |
13,390
-350
| -3% | -$21.8K | 0.06% | 122 |
|
|
2020
Q4 | $852K | Hold |
13,740
| – | – | 0.06% | 116 |
|
|
2020
Q3 | $828K | Hold |
13,740
| – | – | 0.06% | 113 |
|
|
2020
Q2 | $808K | Hold |
13,740
| – | – | 0.07% | 116 |
|
|
2020
Q1 | $766K | Sell |
13,740
-350
| -2% | -$21.4K | 0.08% | 107 |
|
|
2019
Q4 | $904K | Sell |
14,090
-1,500
| -10% | -$85.9K | 0.07% | 119 |
|
|
2019
Q3 | $791K | Buy |
15,590
+2,944
| +23% | +$138K | 0.07% | 125 |
|
|
2019
Q2 | $573K | Buy |
+12,646
| New | +$589K | 0.05% | 148 |
|
|
2017
Q2 | – | Sell |
-87,925
| Closed | -$4.78M | – | 159 |
|
|
2017
Q1 | $4.78M | Sell |
87,925
-6,328
| -7% | -$347K | 0.47% | 72 |
|
|
2016
Q4 | $5.51M | Sell |
94,253
-7,488
| -7% | -$409K | 0.58% | 66 |
|
|
2016
Q3 | $5.49M | Sell |
101,741
-18,356
| -15% | -$1.18M | 0.55% | 67 |
|
|
2016
Q2 | $8.83M | Sell |
120,097
-8,255
| -6% | -$583K | 0.86% | 54 |
|
|
2016
Q1 | $8.2M | Sell |
128,352
-31,459
| -20% | -$1.98M | 0.82% | 53 |
|
|
2015
Q4 | $11M | Sell |
159,811
-140,819
| -47% | -$9.31M | 1.15% | 32 |
|
|
2015
Q3 | $17.8M | Sell |
300,630
-21,625
| -7% | -$1.37M | 1.83% | 10 |
|
|
2015
Q2 | $21.4M | Buy |
322,255
+433
| +0.1% | +$28.5K | 2.02% | 9 |
|
|
2015
Q1 | $20.8M | Sell |
321,822
-11,422
| -3% | -$715K | 2.08% | 9 |
|
|
2014
Q4 | $19.7M | Sell |
333,244
-34,019
| -9% | -$1.92M | 2% | 11 |
|
|
2014
Q3 | $18.8M | Buy |
367,263
+23,913
| +7% | +$1.19M | 2% | 10 |
|
|
2014
Q2 | $16.7M | Buy |
343,350
+42,426
| +14% | +$2.09M | 1.62% | 16 |
|
|
2014
Q1 | $15.6M | Buy |
300,924
+298,525
| +12,444% | +$15.9M | 1.64% | 19 |
|
|
2013
Q4 | $128K | Hold |
2,399
| – | – | 0.01% | 210 |
|
|
2013
Q3 | $111K | Sell |
2,399
-734
| -23% | -$32.2K | 0.01% | 216 |
|
|
2013
Q2 | $140K | Buy |
+3,133
| New | +$136K | 0.02% | 212 |
|
Other funds holding BMY
VCM
VPM
Chilton Capital Management's BMY Position: Q1 2026 in Review
Chilton Capital Management increased its Bristol-Myers Squibb (BMY) stake by 178% in Q1 2026, buying an estimated $3.73K and bringing the position to 100 shares worth $6.07K. The position accounts for ﹤0.01% of the portfolio, ranked #526.
Chilton Capital Management first reported a position in BMY in Q2 2013 and has held it in 44 quarters since. The position peaked at $21.4M in Q2 2015. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Chilton Capital Management held 100 shares of Bristol-Myers Squibb worth $6.07K as of Q1 2026.
- Chilton Capital Management bought 64 Bristol-Myers Squibb shares in Q1 2026, an estimated $3.73K.
- Bristol-Myers Squibb made up ﹤0.01% of Chilton Capital Management's portfolio in Q1 2026, its #526 holding.
- Chilton Capital Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 44 quarters since.
- Chilton Capital Management's Bristol-Myers Squibb position peaked at $21.4M in Q2 2015.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Chilton Capital Management's 13F filing for Q1 2026, filed 11 May 2026.